{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:56:55Z","timestamp":1790024215253,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006302","name":"Universidad de Alcal\u00e1","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006302","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The recombinant zoster vaccine (Shingrix) was recently approved for the prevention of herpes zoster reactivation in adults aged\u2009\u2265\u200950\u00a0years. While its effectiveness has been widely demonstrated, its safety profile and potential adverse effects remain uncertain. We report the first case of lupus induced by the Shingrix vaccine. An 85-year-old woman was evaluated in the hospital due to a pleuropericarditis with pleural and pericardial effusion. Test for anti-nuclear antibody was positive at a titer of 1:640 with a homogeneous pattern, as well as for IgG anti-cardiolipin antibodies. Infectious or malignant etiologies were excluded. A diagnosis of Shingrix vaccine-induced lupus was suspected, and a short course of prednisone was initiated. The patient's symptoms resolved within the first two months, and after one year of follow-up, both the antinuclear and anti-cardiolipin IgG antibodies were negative. Although many drug categories have been associated with the development of drug-induced lupus erythematosus (DILE), it remains unclear whether vaccine-induced immune system upregulation could trigger the onset of systemic lupus. However, particularly after the introduction of the SARS-CoV2 vaccine, cases of cutaneous and systemic lupus induced by vaccines have been reported, and the serological pattern appears to be different from that observed in drug-induced lupus. Our case details a critical adverse effect observed in a patient who received the zoster vaccine. This finding is particularly relevant given the ongoing widespread vaccination campaigns and the global public health implications. Vaccine-induced lupus should be suspected following vaccination in the presence of cutaneous or systemic lupus symptoms, particularly serositis or renal involvement, when no other cause can be identified. The diagnosis is supported by positive antinuclear antibodies and other laboratory abnormalities, such as decreased complement levels or positivity for other antibodies, including antiphospholipid antibodies.\n<jats:table-wrap>\n              <jats:table>\n                <jats:tbody>\n                  <jats:tr>\n                    <jats:td align=\"left\" colspan=\"2\">\n                      <jats:bold>Key Points<\/jats:bold>\u2022 The varicella-zoster vaccine will be administered to a large percentage of the population, which could lead to an increase in adverse effects that have not yet been described. This article reports the first documented case of lupus induced by the varicella-zoster vaccine.\u2022 The diagnosis of Drug-induced lupus erythematosus (DILE) requires a low threshold of suspicion.\u2022 Clinical manifestations in DILE are usually milder, and it often presents with general symptoms, arthralgia, serositis, and hematologic abnormalities.\u2022 The autoimmune profile of vaccine-induced lupus appears to differ from that of drug-induced lupus, being characterized by a higher frequency of positive antinuclear antibodies (ANA), antiphospholipid antibodies, and hypocomplementemia, with a lower prevalence of anti-histone antibodies.<\/jats:td>\n                  <\/jats:tr>\n                <\/jats:tbody>\n              <\/jats:table>\n            <\/jats:table-wrap>\n          <\/jats:p>","DOI":"10.1007\/s10067-025-07529-2","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T22:07:36Z","timestamp":1749679656000},"page":"3119-3125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["First case of lupus induced by the Shingrix vaccine: a case report and literature review"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0197-3237","authenticated-orcid":false,"given":"Coral","family":"Ar\u00e9valo-Ca\u00f1as","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ar\u00e9valo-Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melchor \u00c1lvarez","family":"de Mon-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"issue":"22","key":"7529_CR1","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","volume":"352","author":"MN Oxman","year":"2005","unstructured":"Oxman MN et al (2005) A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352(22):2271\u20132284. https:\/\/doi.org\/10.1056\/NEJMoa051016","journal-title":"N Engl J Med"},{"issue":"11","key":"7529_CR2","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL et al (2016) Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 375(11):1019\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1603800","journal-title":"N Engl J Med"},{"issue":"12","key":"7529_CR3","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s40266-018-0603-x","volume":"35","author":"YY Syed","year":"2018","unstructured":"Syed YY (2018) Recombinant zoster vaccine (Shingrix\u00ae): a review in herpes zoster. Drugs Aging 35(12):1031\u20131040. https:\/\/doi.org\/10.1007\/s40266-018-0603-x","journal-title":"Drugs Aging"},{"issue":"8","key":"7529_CR4","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1093\/gerona\/gly218","volume":"74","author":"KE Schmader","year":"2019","unstructured":"Schmader KE et al (2019) The impact of reactogenicity after the first dose of recombinant zoster vaccine on the physical functioning and quality of life of older adults: an open-label, phase III trial. J Gerontol Series A, Biol Sci Med Sci 74(8):1217\u20131224. https:\/\/doi.org\/10.1093\/gerona\/gly218","journal-title":"J Gerontol Series A, Biol Sci Med Sci"},{"issue":"18","key":"7529_CR5","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1016\/j.vaccine.2019.03.043","volume":"37","author":"M L\u00f3pez-Fauqued","year":"2019","unstructured":"L\u00f3pez-Fauqued M et al (2019) Safety profile of the adjuvanted recombinant zoster vaccine: pooled analysis of two large randomised phase 3 trials. Vaccine 37(18):2482\u20132493. https:\/\/doi.org\/10.1016\/j.vaccine.2019.03.043","journal-title":"Vaccine"},{"issue":"9","key":"7529_CR6","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.autrev.2018.03.016","volume":"17","author":"A Vaglio","year":"2018","unstructured":"Vaglio A et al (2018) Drug-induced lupus: traditional and new concepts. Autoimmun Rev 17(9):912\u2013918. https:\/\/doi.org\/10.1016\/j.autrev.2018.03.016","journal-title":"Autoimmun Rev"},{"issue":"5","key":"7529_CR7","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/BOR.0000000000000522","volume":"30","author":"Y He","year":"2018","unstructured":"He Y, Sawalha AH (2018) Drug-induced lupus erythematosus: an update on drugs and mechanisms. Curr Opin Rheumatol 30(5):490\u2013497. https:\/\/doi.org\/10.1097\/BOR.0000000000000522","journal-title":"Curr Opin Rheumatol"},{"key":"7529_CR8","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1196\/annals.1422.019","volume":"1108","author":"AT Borchers","year":"2007","unstructured":"Borchers AT et al (2007) Drug-induced lupus. Ann N Y Acad Sci 1108:166\u201382. https:\/\/doi.org\/10.1196\/annals.1422.019","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"7529_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00403-008-0895-5","volume":"301","author":"CD Vedove","year":"2009","unstructured":"Vedove CD et al (2009) Drug-induced lupus erythematosus. Arch Dermatol Res 301(1):99\u2013105. https:\/\/doi.org\/10.1007\/s00403-008-0895-5","journal-title":"Arch Dermatol Res"},{"issue":"10","key":"7529_CR10","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1177\/09612033211024355","volume":"30","author":"A Mason","year":"2021","unstructured":"Mason A et al (2021) Lupus, vaccinations and COVID-19: What we know now. Lupus 30(10):1541\u20131552. https:\/\/doi.org\/10.1177\/09612033211024355","journal-title":"Lupus"},{"key":"7529_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.5070\/D329562421","volume":"29","author":"G Famularo","year":"2023","unstructured":"Famularo G et al (2023) COVID-19 vaccine-induced cutaneous lupus erythematosus. Dermatol Online J 29:5. https:\/\/doi.org\/10.5070\/D329562421","journal-title":"Dermatol Online J"},{"issue":"3","key":"7529_CR12","doi-asserted-by":"publisher","first-page":"266","DOI":"10.23736\/S2784-8671.23.07373-5","volume":"158","author":"E Magnaterra","year":"2023","unstructured":"Magnaterra E et al (2023) Subacute cutaneous lupus erythematosus induced by Pfizer COVID-19 vaccine. Ital J Dermatol Venereol 158(3):266\u2013267. https:\/\/doi.org\/10.23736\/S2784-8671.23.07373-5","journal-title":"Ital J Dermatol Venereol"},{"issue":"12","key":"7529_CR13","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1007\/s00296-022-05203-3","volume":"42","author":"I Sagy","year":"2022","unstructured":"Sagy I et al (2022) New-onset systemic lupus erythematosus following BNT162b2 mRNA COVID-19 vaccine: a case series and literature review. Rheumatol Int 42(12):2261\u20132266. https:\/\/doi.org\/10.1007\/s00296-022-05203-3","journal-title":"Rheumatol Int"},{"issue":"4","key":"7529_CR14","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.kint.2022.01.013","volume":"101","author":"HJ Kim","year":"2022","unstructured":"Kim HJ et al (2022) New-onset class III lupus nephritis with multi-organ involvement after COVID-19 vaccination. Kidney Int 101(4):826\u2013828. https:\/\/doi.org\/10.1016\/j.kint.2022.01.013","journal-title":"Kidney Int"},{"issue":"6","key":"7529_CR15","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.kint.2021.09.009","volume":"100","author":"MF Zavala-Miranda","year":"2021","unstructured":"Zavala-Miranda MF et al (2021) New-onset systemic lupus erythematosus beginning as class V lupus nephritis after COVID-19 vaccination. Kidney Int 100(6):1340\u20131341. https:\/\/doi.org\/10.1016\/j.kint.2021.09.009","journal-title":"Kidney Int"},{"issue":"3","key":"7529_CR16","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s12185-021-03243-2","volume":"115","author":"D Hidaka","year":"2022","unstructured":"Hidaka D et al (2022) New-onset Evans syndrome associated with systemic lupus erythematosus after BNT162b2 mRNA COVID-19 vaccination. Int J Hematol 115(3):424\u2013427. https:\/\/doi.org\/10.1007\/s12185-021-03243-2","journal-title":"Int J Hematol"},{"key":"7529_CR17","doi-asserted-by":"publisher","first-page":"6436839","DOI":"10.1155\/2022\/6436839","volume":"2022","author":"L B\u00e1ez-Negr\u00f3n","year":"2022","unstructured":"B\u00e1ez-Negr\u00f3n L, Vil\u00e1 LM (2022) New-onset systemic lupus erythematosus after mRNA SARS-CoV-2 vaccination. Case Rep Rheumatol 2022:6436839. https:\/\/doi.org\/10.1155\/2022\/6436839","journal-title":"Case Rep Rheumatol"},{"issue":"5","key":"7529_CR18","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s10067-022-06097-z","volume":"41","author":"AM N","year":"2022","unstructured":"N AM et al (2022) Systemic lupus erythematosus with acute pancreatitis and vasculitic rash following COVID-19 vaccine: a case report and literature review. Clin Rheumatol 41(5):1577\u20131582. https:\/\/doi.org\/10.1007\/s10067-022-06097-z","journal-title":"Clin Rheumatol"},{"issue":"10","key":"7529_CR19","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/qjmed\/hcab229","volume":"114","author":"A Nune","year":"2021","unstructured":"Nune A et al (2021) The Emergence of new-onset SLE following SARS-CoV-2 vaccination. QJM: Mon J Assoc Phys 114(10):739\u2013740. https:\/\/doi.org\/10.1093\/qjmed\/hcab229","journal-title":"QJM: Mon J Assoc Phys"},{"issue":"10","key":"7529_CR20","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1111\/jocd.14386","volume":"20","author":"S Patil","year":"2021","unstructured":"Patil S, Patil A (2021) Systemic lupus erythematosus after COVID-19 vaccination: a case report. J Cosmet Dermatol 20(10):3103\u20133104. https:\/\/doi.org\/10.1111\/jocd.14386","journal-title":"J Cosmet Dermatol"},{"key":"7529_CR21","doi-asserted-by":"publisher","first-page":"9698138","DOI":"10.1155\/2022\/9698138","volume":"2022","author":"Y Raviv","year":"2022","unstructured":"Raviv Y et al (2022) First presentation of systemic lupus erythematosus in a 24-year-old male following mRNA COVID-19 vaccine. Case Rep Rheumatol 2022:9698138. https:\/\/doi.org\/10.1155\/2022\/9698138","journal-title":"Case Rep Rheumatol"},{"issue":"5","key":"7529_CR22","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1007\/s10067-022-06126-x","volume":"41","author":"C Lemoine","year":"2022","unstructured":"Lemoine C et al (2022) Systemic lupus erythematous after Pfizer COVID-19 vaccine: a case report. Clin Rheumatol 41(5):1597\u20131601. https:\/\/doi.org\/10.1007\/s10067-022-06126-x","journal-title":"Clin Rheumatol"},{"issue":"1","key":"7529_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/mrcr\/rxac018","volume":"7","author":"S Molina-Rios","year":"2023","unstructured":"Molina-Rios S et al (2023) Systemic lupus erythematosus and antiphospholipid syndrome after COVID-19 vaccination. A case report. Mod Rheumatol Case Rep 7(1):43\u201346. https:\/\/doi.org\/10.1093\/mrcr\/rxac018","journal-title":"Mod Rheumatol Case Rep"},{"issue":"2","key":"7529_CR24","doi-asserted-by":"publisher","first-page":"e21917","DOI":"10.7759\/cureus.21917","volume":"14","author":"I Kaur","year":"2022","unstructured":"Kaur I et al (2022) COVID-19 vaccination as a potential trigger for new-onset systemic lupus erythematosus. Cureus 14(2):e21917. https:\/\/doi.org\/10.7759\/cureus.21917","journal-title":"Cureus"},{"issue":"1","key":"7529_CR25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s41927-022-00313-8","volume":"6","author":"MC Nelson","year":"2022","unstructured":"Nelson MC et al (2022) Presentation of SLE after COVID vaccination in a pediatric patient. BMC Rheumatol 6(1):81\u201320. https:\/\/doi.org\/10.1186\/s41927-022-00313-8","journal-title":"BMC Rheumatol"},{"issue":"2","key":"7529_CR26","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1177\/09612033231222390","volume":"33","author":"A Salas","year":"2024","unstructured":"Salas A et al (2024) COVID vaccine-induced lupus nephritis: Case report and review of the literature. Lupus 33(2):176\u2013182. https:\/\/doi.org\/10.1177\/09612033231222390","journal-title":"Lupus"},{"issue":"11","key":"7529_CR27","doi-asserted-by":"publisher","first-page":"e733","DOI":"10.1111\/jdv.17514","volume":"35","author":"A Kreuter","year":"2021","unstructured":"Kreuter A et al (2021) Transition of cutaneous into systemic lupus erythematosus following adenoviral vector-based SARS-CoV-2 vaccination. J Eur Acad Dermatol Venereol: JEADV 35(11):e733\u2013e735. https:\/\/doi.org\/10.1111\/jdv.17514","journal-title":"J Eur Acad Dermatol Venereol: JEADV"},{"issue":"3","key":"7529_CR28","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/73152","volume":"6","author":"A Kretz-Rommel","year":"2000","unstructured":"Kretz-Rommel A, Rubin RL (2000) Disruption of positive selection of thymocytes causes autoimmunity. Nat Med 6(3):298\u2013305. https:\/\/doi.org\/10.1038\/73152","journal-title":"Nat Med"},{"issue":"3","key":"7529_CR29","doi-asserted-by":"publisher","first-page":"e89780","DOI":"10.1172\/jci.insight.89780","volume":"2","author":"C Carmona-Rivera","year":"2017","unstructured":"Carmona-Rivera C et al (2017) A role for muscarinic receptors in neutrophil extracellular trap formation and levamisole-induced autoimmunity. JCI Insight 2(3):e89780. https:\/\/doi.org\/10.1172\/jci.insight.89780","journal-title":"JCI Insight"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07529-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07529-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07529-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T07:46:43Z","timestamp":1751874403000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07529-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7529"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07529-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case report is based on routine clinical care and does not constitute a clinical trial. Ethical approval was not required, as the information was obtained and reported in accordance with standard clinical practice. Written informed consent was obtained from the patient for the use of their anonymized clinical information for academic and publication purposes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The patient provided written informed consent for the publication of this case report, including any accompanying images or data, ensuring anonymity and confidentiality.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}